 |
|
|
| Internet Search |
|
Stock Search |
|
|
|
|
|
HEMISPHERX BIOPHA, (HEB) Stock Research Free Stock Rating
|
|
| |
| Company Profile |
| |
|
Hemispherx Biopharma, Inc. is a biopharmaceutical company. It engages in the manufacture and clinical development of new drug entities for the treatment of viral and immune-based chronic disorders. Its flagship products include Alferon and the experimental immunotherapeutics / antivirals, Ampligen, and Oragens. These proteins, approved for a category of sexually transmitted disease infection and experimental nucleic acids, are being developed for chronic viral diseases and disorders of the immune system, including human papillomaviruses, human immunodeficiency virus, chronic fatigue syndrome, and hepatitis. The company's platform technology includes large and small agent components for the potential treatment of various chronic viral infections. As of May 17, 2004, Hemispherx had approximately 400 patents comprising its core intellectual property estate, a commercialized product (Alferon N), and Good Manufacturing Practices certified manufacturing facilities for its pharma products. The company was formerly known as HEM research, Inc. and then as Hem Pharmaceutical Corp. It was founded in 1966 and is headquartered in Philadelphia, Pennsylvania.
|
|
|
|
|
